EPZ004777 formate
Based on 11 publication(s) in Google Scholar
EPZ004777 formate is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 formate reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 formate selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 formate can be used for the study of leukemia.
For research use only. We do not sell to patients.
- Formula: C29H43N7O6
- Molecular Weight:585.70
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
DOT1L 0.4 nM () |
Chemical Information
-
Molecular Weight 585.70
-
Formula C29H43N7O6
-
SMILES
O=CO.NC1=NC=NC2=C1C=CN2[C@H]3[C@H](O)[C@H](O)[C@@H](CN(C(C)C)CCCNC(NC(C=C4)=CC=C4C(C)(C)C)=O)O3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
Targeting DOT1L Reactivates HERV-K to Drive Cell-Autonomous and Paracrine Senescence in Adenocarcinoma of the Esophagogastric Junction. [Abstract]2026 Jul 15;86(14):3588-3603. PMID: 42084229 -
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Sci Adv
Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway. [Abstract]2023 Jun 2;9(22):eadc9273. PMID: 37256945
EPZ004777 formate purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jun 2;9(22):eadc9273. [Abstract]
H3K79me2 levels in HCI-H460 cells expressing WT or R231Q DOT1L after treatment with different concentrations (0.5, and 5 μM, 9 days) of DOT1Lis (SGC0946, EPZ004777, and EPZ5676)
-
Acta Pharmacol Sin
2022 Feb;43(2):457-469. PMID: 33850273 -
Diabetes
Molecular Mechanisms of Human Pancreatic Islet Dysfunction Under Overnutrition Metabolic Stress. [Abstract]2025 Oct 1;74(10):1825-1838. PMID: 40773375 -
Oncogene
The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia. [Abstract]2024 Jun;43(25):1900-1916. PMID: 38671157
EPZ004777 formate purchased from MedChemExpress. Usage Cited in: Oncogene. 2024 Jun;43(25):1900-1916. [Abstract]
LSCs from Atm+/+ and Atm−/− F2 recipients were treated with different doses of the DOT1L inhibitor (EPZ004777) for 7 days. The cell viability was then determined by the CCK8 assay.
-
Cell Syst
A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]2018 Apr 25;6(4):424-443.e7. PMID: 29655704 -
Oncogenesis
Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis. [Abstract]2021 Jul 12;10(7):48. PMID: 34253709
EPZ004777 formate purchased from MedChemExpress. Usage Cited in: Oncogenesis. 2021 Jul 12;10(7):48. [Abstract]
The indicated ovarian cancer cell lines were treated with various concentrations of DOT1L inhibitors EPZ004777 for 48 h. H3K79dimethyl marks were then measured. Histone H3 and ACTINB proteins were measured as loading controls. The results demonstrated that EPZ004777 effectively inhibited H3K79 dimethylation (H3K79me2) modification.
EPZ004777 formate purchased from MedChemExpress. Usage Cited in: Oncogenesis. 2021 Jul 12;10(7):48. [Abstract]
The indicated ovarian cancer cell lines were treated with the DOT1L inhibitor EPZ004777 (10 µM) and SGC0946 (20 µM) for 3 days and analyzed for cell survival in MTT assays. The results showed that EPZ004777 could effectively inhibit the short-term growth of ovarian cancer cells.
EPZ004777 formate purchased from MedChemExpress. Usage Cited in: Oncogenesis. 2021 Jul 12;10(7):48. [Abstract]
IGROV-1 cells were injected subcutaneously into the flanks of NSG mice (n = 5). The mice were treated with EPZ004777 (50 mg/kg) intraperitoneally every day and analyzed for tumor growth. Tumor sizes were measured each week and the average tumor volume is plotted (E). Representative images of the tumors from the mice after 6 weeks of EPZ004777 treatment are shown (F). The results showed that treatment with EPZ004777, a DOT1L inhibitor, elicited inhibitory effects on ovarian cancer tumor growth in vivo in xenograft models.
-
Hematol Oncol
Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion. [Abstract]2019 Dec;37(5):617-625. PMID: 31701557 -
-
Purity & Documentation
References
[1]. Daigle SR, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12;20(1):53-65. [Content Brief]
[2]. Chen L, et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013 Apr;27(4):813-22. [Content Brief]
[3]. Deshpande AJ, et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.Blood. 2013 Mar 28;121(13):2533-41. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)